Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARK7 | Q99497 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | JAK1 | P23458 | 2/20 | 0.31 |
| ▸ | TYK2 | P29597 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL666932 | 0.85 | HSPA5 (0.46) | PARK7 | |
| SCHEMBL665288 | 0.84 | PARK7 (0.53) | PARK7 | |
| SCHEMBL665474 | 0.78 | PARK7 (0.49) | PARK7RAB9A | |
| SCHEMBL665039 | 0.76 | PARK7 (0.50) | PARK7RAB9A | |
| Dehydroxymethylepoxyquinomicin SCHEMBL1671089 | 0.75 | PARK7 (0.54) | PARK7RAB9A | |
| Dehydroxymethylepoxyquinomicin SCHEMBL1669417 | 0.75 | PARK7 (0.54) | PARK7RAB9A | |
| Dehydroxymethylepoxyquinomicin SCHEMBL14491796 | 0.75 | PARK7 (0.54) | PARK7RAB9A | |
| Dehydroxymethylepoxyquinomicin SCHEMBL14504317 | 0.75 | PARK7 (0.54) | PARK7RAB9A | |
| SCHEMBL115782 | 0.74 | PARK7 (0.51) | PARK7CYP3A4RAB9A | |
| SCHEMBL665471 | 0.72 | PARK7 (0.57) | PARK7RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046357-A1 | Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB) | PROFECTUS BIOSCIENCES, INC. (US) | 2012-02-23 | — | — | US | claimed |
| US-20120046357-A1 | Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB) | PROFECTUS BIOSCIENCES, INC. (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046357-A1 | Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB) | NFKBIA, IKBKB, NFKB1 | PARK7 3384/4885DPP4 1016/4885JAK2 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.